RECURRENT LANGERHANS CELL HISTIOCYTOSIS
Clinical trials for RECURRENT LANGERHANS CELL HISTIOCYTOSIS explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LANGERHANS CELL HISTIOCYTOSIS trials appear
Sign up with your email to follow new studies for RECURRENT LANGERHANS CELL HISTIOCYTOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare immune cell cancer: drug trial launches
Disease control Recruiting nowThis study tests a drug called tovorafenib (DAY101) in children and young adults (ages 6 months to 22 years) with Langerhans cell histiocytosis that has returned or not responded to treatment. The drug works by blocking enzymes that help cancer cells grow. Researchers will check …
Matched conditions: RECURRENT LANGERHANS CELL HISTIOCYTOSIS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill Q702 aims to outsmart blood cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called Q702 in people with various blood cancers and related disorders that have not responded to standard treatments. Q702 is designed to help the immune system attack cancer cells and help the bone marrow make healthy blood cells. Th…
Matched conditions: RECURRENT LANGERHANS CELL HISTIOCYTOSIS
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC